Galecto Inc. Stock Price, News & Analysis

BOSTON, Feb. 1, 2023 (GLOBE NEWSWIRE) -- Galecto, a clinical-stage biotechnology company focused on fibrosis and cancer treatments, will present at the SVB Securities Global Biopharma Conference from February 14-16, 2023. The presentation is scheduled for February 14th at 8:00 AM EST. A live webcast will be available on Galecto's Investor website, along with a replay following the event.

Currently, Galecto is developing small molecule inhibitors targeting galectin-3 and LOXL2, with four ongoing Phase 2 trials including treatments for idiopathic pulmonary fibrosis and non-small cell lung cancer.

Galecto, Inc. (NASDAQ: GLTO) announced an intermediate assessment of its Phase 2 MYLOX-1 trial for GB2064, an oral LOXL2 inhibitor targeting myelofibrosis. The study showed that 4 out of 5 evaluable patients experienced a significant reduction in collagen fibrosis, indicating potential disease-modifying effects. The results will be presented at the ASH Annual Meeting on December 10, 2022. The trial focuses on patients refractory to JAK inhibitors, with GB2064 administered at 1000mg twice daily. The preliminary findings suggest that GB2064 effectively engages its target and penetrates fibrotic bone marrow.

Galecto, Inc. (NASDAQ: GLTO), a biotechnology company, reported its Q3 2022 results, highlighting successful outcomes from clinical trials. The Phase 1b/2a GULLIVER-2 trial showed GB1211 reduced liver impairment signs in patients with cirrhosis. The Phase 2a MYLOX-1 trial indicated GB2064 effectively reduced collagen fibrosis in myelofibrosis patients. Although the net loss was $13.7 million, cash reserves of $75.9 million are expected to sustain operations into mid-2024. Upcoming milestones include top-line results from the GALACTIC-1 trial in mid-2023.

Galecto, Inc. (NASDAQ: GLTO) reported promising topline results from its Phase 1b/2a GULLIVER-2 trial of GB1211, focusing on severe liver diseases. The trial showed statistically significant reductions in liver enzymes ALT, AST, and GGT after 12 weeks, with GB1211 demonstrating encouraging results in various liver function markers. The data indicates potential liver protection and improvement in patients with decompensated cirrhosis. Further development for GB1211 is anticipated, given its favorable safety profile and encouraging efficacy.

BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Galecto (NASDAQ: GLTO), a clinical-stage biotechnology company, will present at the Jefferies London Healthcare Conference on November 16, 2022, at 7:25 am GMT. The presentation will focus on its advancements in galectin biology aimed at treating fibrosis and cancer. A live webcast can be accessed here and a replay will be available on Galecto's Investor website following the event. The company is currently developing therapies for idiopathic pulmonary fibrosis, myelofibrosis, liver cirrhosis, and non-small cell lung cancer.

Galecto (NASDAQ: GLTO) presented data from its completed Phase 1b/2a GULLIVER-2 trial at The Liver Meeting 2022. The trial evaluated GB1211, a galectin-3 inhibitor, for severe liver diseases. Topline data showed GB1211 was well-tolerated, with encouraging clinical efficacy, including reduced liver enzyme levels and improved liver fat measurements. The results support further development of GB1211 in severe cirrhosis, addressing a critical unmet need for treatment options. A webinar is scheduled for November 8, 2022, to discuss the findings in detail.

Galecto, Inc. (NASDAQ: GLTO) announced a collaboration for a Phase 2 trial at Providence Cancer Institute to evaluate the safety and efficacy of GB1211, a galectin-3 inhibitor, combined with pembrolizumab (Keytruda). This investigator-initiated trial aims to counteract checkpoint inhibitor resistance in melanoma and head and neck squamous cell carcinoma (HNSCC) patients. The randomized trial will start in 2023, with top-line results expected by 2025. GB1211 has shown promise in previous studies, demonstrating a well-tolerated profile and potential anti-cancer effects.

Galecto, Inc. (NASDAQ: GLTO) announced a live conference call and webcast on November 8, 2022, at 8:00 am ET to discuss topline data from the GULLIVER-2 trial for liver cirrhosis. The trial assesses the safety and efficacy of GB1211, an oral galectin-3 inhibitor, in up to 54 participants with decompensated cirrhosis. The trial includes both randomized and open-label study parts, focusing on pharmacokinetics and therapeutic potential. Interested individuals can join the webcast through a provided link, and a replay will be accessible on the investor relations website.

Galecto, Inc. (NASDAQ: GLTO) announced positive results from its Phase 2a MYLOX-1 trial of GB2064 for myelofibrosis on September 29, 2022. Out of five evaluable patients, four showed a ≥ 1-grade reduction in collagen fibrosis after six months of GB2064 treatment, indicating potential disease modification. Patients also exhibited stable hematological parameters without the need for transfusions. The drug demonstrated a generally acceptable tolerability profile, though some patients discontinued due to adverse events. Company leadership highlighted these results as a proof of principle for GB2064's anti-fibrotic effects.